Announcement
24.04.2013



NeuroSearch A/S (NEUR) has received information from UBS AG, Switzerland, that the company has sold its NeuroSearch shares and now holds 0% of the NeuroSearch share capital.


René Schneider
CEO



Contact person
René Schneider, CEO, telephone: +45 4460 8700 or +45 2911 2097



About NeuroSearch
NeuroSearch A/S (NEUR) is listed on NASDAQ OMX Copenhagen A/S. The company’s product pipeline comprises ordopidine and seridopidine, which have both completed phase I studies, as well as tesofensine, which has completed phase II, and NS2359 which has completed phase I. All drug candidates exert their effect in the central nervous system.